基本信息
浏览量:117
职业迁徙
个人简介
Professional Interests
T lymphocytes play a central role in the initiation and regulation of the adaptive immune response to antigen, whether foreign or native. The outcome of T cell engagement of antigen is determined by both positive costimulation and negative coinhibition, generated mainly by the interaction between the B7 ligand family and their receptor CD28 family. We have recently discovered new members of the T cell costimulatory/coinhibitory B7 family and CD28 family including B7x, HHLA2 and TMIGD2, and have contributed to other immune checkpoints ICOS, PD-L1/PD-1, B7-H3, Tim-3, BTNL2, etc. We are using a variety of experimental approaches (gene knock-out mice, transgenic mice, monoclonal antibodies,crystal structure, patients samples, etc) to understand how new immune checkpoints regulate T cell activation and tolerance. Current emphasis in the lab is placed in the following areas: 1) Novel drugs development: Translational medicine of new immune checkpoints; 2) In vivo functions of new immune checkpoint pathways; 3) Human cancer-associated new B7/CD28 pathways and cancer immunotherapy; 4) Roles of new immune checkpoint pathways in autoimmune diseases/metabolic diseases and immunotherapy; 5) Relationship between new B7/CD28 pathways and infection; 6) Functional and structural characterization of new members of the immunoglobulin superfamily.
Our goal is to elucidate the mechanisms by which new immune checkpoints regulate T cells in peripheral non-lymphoid organs, and to translate the lessons learned in these studies towards developing new therapeutic strategies for cancers, autoimmune disorders, metabolic diseases, infectious diseases, and transplantation rejection. Our research have won attention from biopharmaceutical industry and ventures.
Since 2008 the lab has mentored total 45 trainees of MD-PhD or PhD students, postdoctoral fellows, clinical fellows, and visiting scientists. Many of trainees have subsequently moved on to independent careers in academic universities, medical centers, biopharmaceutical industry, and US government agencies.
T lymphocytes play a central role in the initiation and regulation of the adaptive immune response to antigen, whether foreign or native. The outcome of T cell engagement of antigen is determined by both positive costimulation and negative coinhibition, generated mainly by the interaction between the B7 ligand family and their receptor CD28 family. We have recently discovered new members of the T cell costimulatory/coinhibitory B7 family and CD28 family including B7x, HHLA2 and TMIGD2, and have contributed to other immune checkpoints ICOS, PD-L1/PD-1, B7-H3, Tim-3, BTNL2, etc. We are using a variety of experimental approaches (gene knock-out mice, transgenic mice, monoclonal antibodies,crystal structure, patients samples, etc) to understand how new immune checkpoints regulate T cell activation and tolerance. Current emphasis in the lab is placed in the following areas: 1) Novel drugs development: Translational medicine of new immune checkpoints; 2) In vivo functions of new immune checkpoint pathways; 3) Human cancer-associated new B7/CD28 pathways and cancer immunotherapy; 4) Roles of new immune checkpoint pathways in autoimmune diseases/metabolic diseases and immunotherapy; 5) Relationship between new B7/CD28 pathways and infection; 6) Functional and structural characterization of new members of the immunoglobulin superfamily.
Our goal is to elucidate the mechanisms by which new immune checkpoints regulate T cells in peripheral non-lymphoid organs, and to translate the lessons learned in these studies towards developing new therapeutic strategies for cancers, autoimmune disorders, metabolic diseases, infectious diseases, and transplantation rejection. Our research have won attention from biopharmaceutical industry and ventures.
Since 2008 the lab has mentored total 45 trainees of MD-PhD or PhD students, postdoctoral fellows, clinical fellows, and visiting scientists. Many of trainees have subsequently moved on to independent careers in academic universities, medical centers, biopharmaceutical industry, and US government agencies.
研究兴趣
论文共 178 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Yanhong Li,Yifei Sang,Yunjian Chang,Chunfang Xu,Yikong Lin, Yao Zhang, Philip C N Chiu,William S B Yeung, Haisheng Zhou,Ningzheng Dong, Ling Xu,Jiajia Chen,
SANJAY GOEL,Yan Huang,Ana Acuna-Villaorduna, Catarina Maia,Xingxing Zang, Xiaohua Qi,Juan Lin,Qiang Liu,Radhika Gali, Keerthi Cedona,Wei Zhang, Chenxin Zhang,
crossref(2024)
Nature Communicationsno. 1 (2024): 1-17
Christopher D Nishimura,Devin Corrigan, Xiang Yu Zheng,Phillip M Galbo, Shan Wang, Yao Liu,Yao Wei, Linna Suo, Wei Cui, Nadia Mercado,Deyou Zheng,Cheng Cheng Zhang,
Science advancesno. 19 (2024): eadk1857-eadk1857
Cancersno. 13 (2023): 3372-3372
Yu Liu,Peter John, Kenta Nishitani,Jihong Cui, Christopher D Nishimura,John R Christin, Nicole Couturier,Xiaoxin Ren,Yao Wei,Marc C Pulanco,Phillip M Galbo,Xusheng Zhang,
Developmental cellno. 23 (2023): 2700-2717.e12
J. Yang, A. Sevkoplyas, S. Podsvirova, A. Tyshevich, M. Wang,M. Lee,H. Narvel, K. Zornikova,N. Shin, N. Kotlov,E. Postovalova, L. Paoluzzi,
Annals of Oncology (2023): S1057-S1057
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn